Improved Therapy for PSA Recurrence after Prostatectomy
Mené sur 760 patients atteints d'un cancer de la prostate de stade T2 ou T3 ayant récidivé après une prostatectomie radicale avec lymphadénectomie (durée médiane de suivi : 13 ans), cet essai évalue, du point de vue du taux actuariel de survie globale à 12 ans, l'intérêt d'ajouter à une radiothérapie un traitement anti-androgénique par bicalutamide
In developed countries around the world, prostate cancer is the most common solid neoplastic disease. In the United States, approximately half the men with localized prostate cancer undergo radical prostatectomy.1 Prostate-specific antigen (PSA) levels should be undetectable after surgery; a detectable PSA level usually indicates disease recurrence. Almost uniformly, patients who have progression to metastatic disease and subsequently die from prostate cancer present with a detectable PSA level as the first evidence of cancer recurrence. In many patients, residual or recurrent disease is limited to the prostatic bed or pelvis, a phenomenon that has been confirmed by observations that adjuvant . . .
New England Journal of Medicine , éditorial, 2016